ArticleFrontiers in oncology2026
Impact of adjuvant immunotherapy on prognosis in esophageal squamous cell carcinoma patients following neoadjuvant immunochemotherapy.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The CheckMate-577 trial confirmed that adjuvant nivolumab significantly prolonged disease-free survival (DFS) in patients with esophageal cancer who had residual disease after neoadjuvant chemoradiotherapy (nCRT). However, whether postoperative adjuvant immunotherapy (AIT) is necessary following neoadjuvant immunochemotherapy (nICT) remains highly controversial. This study aims to explore the efficacy of AIT in esophageal squamous cell carcinoma (ESCC) patients who underwent nICT. Methods: A multicenter, retrospective study was conducted on 323 ESCC patients who underwent nICT followed by R0 resection. Patients were divided into AIT group and non-AT group, with further stratification based on pCR status. Stable inverse probability of treatment weighting (sIPTW) was used to balance baseline characteristics. Primary endpoint was overall survival (OS). Secondary endpoints were disease-free survival (DFS) and cancer-specific survival (CSS). Survival outcomes were analyzed using Kaplan-Meier curves. Results: In overall patients, AIT significantly improved OS (2-year OS: 95.8% vs. 84.4%, P = 0.008) and CSS (2-year CSS: 96.8% vs. 89.9%, P = 0.036), while no significant survival benefit from AIT was observed for pCR patients. However, in non-pCR patients, AIT significantly improved OS (2-year OS: 93.5% vs. 78.8%, P = 0.024) and CSS (2-year CSS: 95.0% vs. 85.9%, P = 0.047). No significant differences were observed between adjuvant immunochemotherapy (AICT) and adjuvant immune checkpoint inhibitor monotherapy (AIMT). Conclusion: The study showed that AIT could bring prognosis benefits for patients receiving nICT, especially in non-pCR patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.